Find investors
← Back to all investors
Bill Newlin
ResearchedAngel Investors

Bill Newlin

Director

Angel InvestorsSeed Round
Pitch Bill

Get their honest, personalized take on your startup.

Sign in to pitch Bill

At a glance

Full Name
William R. Newlin II
Title
Director
Firm
Newlin Investment Company (also Founder & majority owner, Black Dog Ventures)
Firm Type
Family private equity / venture capital investor (angel-style early-stage participation)
Investment Stage
Seed / early stage
Sector Focus
Technology, life sciences / medical diagnostics, industrial/advanced materials; plus food & beverage / airport concessions (via Black Dog Ventures)
Geographic Focus
Pittsburgh and the broader U.S. (firm does business in Pittsburgh, Florida and Boston)
Location
Sewickley / Pittsburgh, Pennsylvania (428 Beaver Street, 2nd Floor, Sewickley, PA 15143)

Background

Bill Newlin II (William R. Newlin II) is a Director at Newlin Investment Company, the Sewickley, Pennsylvania–based private equity and venture capital firm founded in 2007 by his father, William R. Newlin — the longtime Pittsburgh business leader often called the "godfather" of the region's tech startup scene. At the firm, Bill II "provides assistance to Newlin Investment Company with respect to advice concerning operations of certain portfolio companies," working alongside the family's investing team on technology, life science, and industrial holdings.

His primary operating venture is Black Dog Ventures, which he founded in 1999 and of which he is the majority owner. Black Dog and its affiliates own and operate roughly 27 food-and-beverage retail locations across eight major U.S. airports, including Baltimore-Washington (BWI), Boston Logan, Cleveland, Washington Dulles, Pittsburgh, Reagan National, New York's JFK, and Nashville. Black Dog Ventures is itself listed among Newlin Investment Company's representative investments, reflecting the overlap between his operating business and the family firm's portfolio.

Because he shares a name with his father, Bill Newlin II is frequently confused with the elder William R. Newlin (Chairman of Newlin Investment Company, former CEO of Buchanan Ingersoll and EVP/Chief Administrative Officer of DICK'S Sporting Goods). The two are distinct individuals with separate profiles on the firm's team page; Bill II's role centers on airport-concessions operating experience and hands-on portfolio-company operational advice rather than the father's board-and-finance legacy.

Investment Thesis & Focus

  • Invests as part of a small, hands-on family firm rather than an institutional fund — Newlin Investment makes "long-term investments in selected growth and value opportunities in technology, industrial and life science markets."
  • Early-stage / seed participation in Pittsburgh-region companies, often university spinouts (Carnegie Mellon, University of Pittsburgh, MIT) commercializing deep-tech and life-science research.
  • Brings operator-level value beyond capital: his own background is in building and running a multi-location food-and-beverage concessions business, so he contributes operational and management guidance to portfolio companies.
  • Aligned with the firm's collaborative, patient-capital ethos — the Newlins treat venture investing as "making investments and learning from them over time" and emphasize supporting the broader startup ecosystem, not just funded companies.

Notable Investments

  • Black Dog Ventures — His own company (founded 1999); ~27 airport food & beverage locations across 8 U.S. airports; listed among the firm's representative investments.
  • Liquid X Printed Metals — Carnegie Mellon spinoff producing functional metallic (conductive) inks for manufacturing.
  • Carmell Therapeutics — Plasma-based bioactive materials for bone and tissue healing (later went public).
  • SpIntellx — University of Pittsburgh spinoff building explainable-AI tools for digital pathology / spatial analytics.
  • Xibus Systems — MIT spinoff developing rapid microbiological testing for pathogens, allergens and spoilage organisms.
  • Sharp Edge Labs — Carnegie Mellon spinoff developing small-molecule drugs for genetic diseases.
  • MediBeacon — Optical diagnostics for real-time kidney-function monitoring.
  • Neuro Kinetics — Neuro-functional diagnostic and assessment tools (sold to Neurolign, 2019).
  • Simcoach Games — Game-based workforce training (sold 2020).
  • Safaba Translation Solutions — Machine-translation software (sold 2015).

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.